Patents by Inventor Aamir Mir

Aamir Mir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11286471
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: March 29, 2022
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells
    Publication number: 20220073892
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 10, 2022
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20220049233
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: November 3, 2021
    Publication date: February 17, 2022
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11198857
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: December 14, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Mad nucleases
    Patent number: 11193115
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: December 7, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
    Publication number: 20210363518
    Abstract: Chemically modified crRNAs and tracrRNAs are provided. crRNAs and tracrRNAs with 5? and/or 3? conjugated moieties are provided. crRNAs and tracrRNAs with modifications in the repeat region of the crRNA or the anti-repeat region of the tracrRNA are provided. Methods of using the crRNAs and tracrRNAs for genome editing with a CRISPR nuclease and kits for performing the same are also provided.
    Type: Application
    Filed: March 18, 2019
    Publication date: November 25, 2021
    Inventors: Erik Joseph SONTHEIMER, Anastasia KHVOROVA, Jonathan Kenneth WATTS, Aamir MIR, Julia Frances ALTERMAN, Matthew Ryan HASSLER, Michael Harry BRODSKY, Alexandre Jean-Marie DEBACKER
  • Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells
    Publication number: 20210355467
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 18, 2021
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Mad nucleases
    Patent number: 11174471
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 16, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • COMPOSITIONS, METHODS, MODULES AND INSTRUMENTS FOR AUTOMATED NUCLEIC ACID-GUIDED NUCLEASE EDITING IN MAMMALIAN CELLS USING MICROCARRIERS
    Publication number: 20210332389
    Abstract: This invention relates to compositions of matter, methods, modules and automated, end-to-end closed instruments for automated mammalian cell growth, reagent bundle creation and mammalian cell transfection followed by nucleic acid-guided nuclease editing in live mammalian cells.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 28, 2021
    Inventors: Phillip Belgrader, Nathan Bade, Christian Siltanen, Aamir Mir, Xi-Jun Chen, Janine Mok, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
  • NOVEL MAD NUCLEASES
    Publication number: 20210324355
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 21, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210301270
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 30, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11104890
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: August 31, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • MAD nucleases
    Patent number: 11085030
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: August 10, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • AUTOMATED MULTI-MODULE CELL PROCESSING METHODS, INSTRUMENTS, AND SYSTEMS
    Publication number: 20210214672
    Abstract: The present disclosure provides compositions, automated multi-module instruments and methods to increase the percentage of edited mammalian cells in a cell population when employing nucleic-acid guided editing.
    Type: Application
    Filed: January 2, 2021
    Publication date: July 15, 2021
    Inventors: Aamir Mir, Erik Zimmerman, Emily Feldman, Benjamin Mijts, Andrew Garst
  • CELL POPULATIONS WITH RATIONALLY DESIGNED EDITS
    Publication number: 20210214671
    Abstract: The present disclosure provides compositions, automated multi-module instruments and methods to increase the percentage of edited mammalian cells in a cell population when employing nucleic-acid guided editing.
    Type: Application
    Filed: January 11, 2020
    Publication date: July 15, 2021
    Inventors: Aamir Mir, Erik Zimmerman, Emily Feldman, Benjamin Mijts, Andrew Garst
  • MAD nucleases
    Patent number: 11053485
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210198641
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 1, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210171923
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 10, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • ENGINEERED ENZYMES
    Publication number: 20210155912
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 27, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11008557
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 18, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon